SCHEMBL207170

SCHEMBL207170

OC1(O)CCCN1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.47
SIGMAR1 Q99720 1/20 0.45
CCR3 P51677 1/20 0.44
CYP3A4 P08684 2/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2D6 P10635 3/20 0.43
NPY1R P25929 1/20 0.41
HTT P42858 1/20 0.41
NPY2R P49146 1/20 0.41
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HIF1A Q16665 1/20 0.40
P2RX1 P51575 1/20 0.40
P2RX3 P56373 1/20 0.40
P2RX4 Q99571 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8936204 0.82 OPRL1 (0.46) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL24696382 0.81 OPRL1 (0.45) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL8663255 0.81 OPRL1 (0.45) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL5067826 0.80 MEN1 (0.46) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL12672699 0.79 MEN1 (0.45) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL5592149 0.79 OPRL1 (0.46) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL3272543 0.78 MEN1 (0.47) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL5466208 0.76 KMT2A (0.46) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL2931788 0.76 MEN1 (0.46) OPRL1MEN1KMT2APOLBSIGMAR1
SCHEMBL25000121 0.76 CYP2D6 (0.43) OPRL1MEN1KMT2APOLBSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829218-B2 Highly active and selective ethylene oligomerization catalyst and method of preparing hexene or octene using the same SK INNOVATION CO., LTD. (KR) 2014-09-09 US disclosed
EP-1405852-B9 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2013-03-27 EP disclosed
EP-2543682-A1 HIGHLY ACTIVE AND HIGHLY SELECTIVE ETHYLENE OLIGOMERIZATION CATALYST, AND PREPARATION METHOD OF HEXENE OR OCTENE USING SAME SK Innovation Co. Ltd. (KR) 2013-01-09 EP disclosed
EP-1405852-B1 DIAMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2012-08-01 EP disclosed
US-20120130086-A1 Highly Active and Selective Ethylene Oligomerization Catalyst and Method of Preparing Hexene or Octene Using the Same SK GLOBAL CHEMICAL CO., LTD. (KR) 2012-05-24 US disclosed
US-8088796-B2 Triamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110312990-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-12-22 US disclosed
EP-2343290-A1 Diamine derivatives as factor X inhibitors Daiichi Sankyo Company, Limited (JP) 2011-07-13 EP disclosed
US-20110077266-A1 Diamine Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-03-31 US disclosed
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
US-7365205-B2 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI SANKYO COMPANY, LIMITED (JP) 2008-04-29 US disclosed
US-7342014-B2 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-11 US disclosed
US-20080015215-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-17 US disclosed
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-11-09 US disclosed
US-20050245565-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1577301-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 EP disclosed
US-20050119486-A1 Diamine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2005-06-02 US disclosed
US-20050020645-A1 Diamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-01-27 US disclosed
EP-1415992-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 EP disclosed
EP-1405852-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130086-A1 Highly Active and Selective Ethylene Oligomerization Catalyst and Method of Preparing Hexene or Octene Using the Same ORC3, OXER1, EXOC1 OPRL1 2323/4885MEN1 695/4885KMT2A 2985/4885
US-20100099660-A1 METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES F2, PLAT, MPL OPRL1 2718/4885MEN1 322/4885KMT2A 2546/4885
US-20060252837-A1 Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X F2, C1S, C9 OPRL1 1013/4885MEN1 726/4885KMT2A 3495/4885
US-20050020645-A1 Diamine derivatives C9, C1S, C1R OPRL1 573/4885MEN1 457/4885KMT2A 3485/4885
US-20080015215-A1 DIAMINE DERIVATIVES C9, C1S, C1R OPRL1 573/4885MEN1 457/4885KMT2A 3485/4885
US-20050245565-A1 Diamine derivatives C9, C1S, C1R OPRL1 573/4885MEN1 457/4885KMT2A 3485/4885
US-20050119486-A1 Diamine derivatives C9, C1S, C1R OPRL1 573/4885MEN1 457/4885KMT2A 3485/4885
US-20110077266-A1 Diamine Derivatives F2, TFPI, F3 OPRL1 4235/4885MEN1 1094/4885KMT2A 1453/4885
US-20110312990-A1 Diamine Derivatives C9, C1S, C1R OPRL1 487/4885MEN1 602/4885KMT2A 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.